Meclizine 12.5/25 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Nausea from Motion Sickness

• Scopolamine transdermal (availability varies)

About Meclizine 12.5/25 mg tabs

Feeling queasy or dizzy? Meclizine 12.5 mg and 25 mg tablets are a common and effective solution for motion sickness and vertigo. At TheDrugClub, we believe essential medications shouldn't break the bank. Discover how our members can access meclizine for an unbeatable $0 co-pay, delivered right to your door.

Meclizine is primarily known for its ability to prevent and treat symptoms associated with motion sickness, such as nausea, vomiting, and dizziness. It's also a go-to medication for managing vertigo, a sensation of spinning or whirling. Whether you're planning a road trip, a cruise, or simply dealing with an inner ear disturbance, meclizine can help stabilize your world. It comes in convenient 12.5 mg and 25 mg tablet strengths, allowing for flexible dosing based on your needs and your doctor's recommendation.

Meclizine belongs to a class of drugs called antihistamines. While commonly associated with allergy relief, meclizine's mechanism of action for motion sickness and vertigo involves its effects on the central nervous system. It works by depressing excitability in the labyrinth (part of the inner ear responsible for balance) and blocking certain receptors in the brain's "vomiting center." Essentially, it helps to calm the signals that cause dizziness and nausea, providing a smoother experience for your body's balance system. It's typically taken about an hour before travel

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Meclizine 12.5/25 mg tabs is approved for (FDA label)

Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.

Source: Read the full FDA label on DailyMed. Label effective date: September 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Meclizine 12.5/25 mg tabs (FDA label)

Tablets 25 mg: oval-shaped, biconvex, two-layered tablet, one yellow to pale yellow layer debossed with “49” and one white to off white layer debossed with “L”. Tablets: 25 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: 21d4a6ee-0a66-45d7-bab9-c5eef399713d. SPL document ID: 5a6ad5f1-af5e-4317-e063-6394a90abe65. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Meclizine 12.5/25 mg tabs (FDA label)

The following adverse reactions associated with the use of meclizine hydrochloride were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported. Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 21d4a6ee-0a66-45d7-bab9-c5eef399713d. SPL document ID: 5a6ad5f1-af5e-4317-e063-6394a90abe65. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Meclizine 12.5/25 mg tabs (FDA label)

Meclizine hydrochloride is contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see Adverse Reactions (6) and Description (11) ] . Meclizine hydrochloride is contraindicated in patients with hypersensitivity to meclizine or any of the inactive ingredients.

Source: FDA prescribing information (DailyMed). Set ID: 21d4a6ee-0a66-45d7-bab9-c5eef399713d. SPL document ID: 5a6ad5f1-af5e-4317-e063-6394a90abe65. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Meclizine 12.5/25 mg tabs (FDA label)

May cause drowsiness: Use caution when driving a car or operating dangerous machinery ( 5.1 ). Potential anticholinergic action: this drug should be prescribed with care to patients with a history of asthma, glaucoma, or enlargement of the prostate gland ( 5.2 ). 5.1 Drowsiness Since drowsiness may occur with use of meclizine hydrochloride, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery. Patients should avoid alcoholic beverages while taking meclizine hydrochloride [see Drug Interactions (7.1) ] . 5.2 Concurrent Medical Conditions Because of its potential anticholinergic action, meclizine hydrochloride should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

Source: FDA prescribing information (DailyMed). Set ID: 21d4a6ee-0a66-45d7-bab9-c5eef399713d. SPL document ID: 5a6ad5f1-af5e-4317-e063-6394a90abe65. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Meclizine 12.5/25 mg tabs (FDA label)

Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors ( 7.2 ). 7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride is administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1) ] . 7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore, there is a possibility for a drug interaction between meclizine hydrochloride and CYP2D6 inhibitors. Therefore, monitor for adverse reactions and clinical effect accordingly.

Source: FDA prescribing information (DailyMed). Set ID: 21d4a6ee-0a66-45d7-bab9-c5eef399713d. SPL document ID: 5a6ad5f1-af5e-4317-e063-6394a90abe65. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.